PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

BACKGROUND: Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However, in lung cancer t...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:PLoS One
मुख्य लेखकों: Schmidt, Lars Henning, Kümmel, Andreas, Görlich, Dennis, Mohr, Michael, Bröckling, Sebastian, Mikesch, Jan Henrik, Grünewald, Inga, Marra, Alessandro, Schultheis, Anne M., Wardelmann, Eva, Müller-Tidow, Carsten, Spieker, Tilmann, Schliemann, Christoph, Berdel, Wolfgang E., Wiewrodt, Rainer, Hartmann, Wolfgang
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Public Library of Science 2015
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4552388/
https://ncbi.nlm.nih.gov/pubmed/26313362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0136023
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन